INTELLIA THERAPEUTICS INC
NASDAQ
US Flag
NTLA

NTLA
INTELLIA THERAPEUTICS INC
US Flag
NASDAQ
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

NTLA Stock Chart

All time

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 211
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar Shows How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Help Center Refer a friend Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out